Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 18, 2020
<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C Turner, Claire Swift, Lucy Kilburn, et al.
JCO Precision Oncology
|
June 30, 2022
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience
Lorenzo Gerratana, Michael Movarek, Firas Wehbe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2019
Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Oukseub Lee, Megan E Sullivan, Yanfei Xu, et al.
Cancers
|
May 14, 2022
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area
Alain Mina, Carlos Galvez, Reem Karmali, et al.
Breast Cancer Research and Treatment
|
March 2, 2011
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
Virginia G Kaklamani, Kalliopi Siziopikou, Denise Scholtens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
Kathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR
|
April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Kathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Journal of Health Psychology
|
July 28, 2025
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study
Dori M Beeler, Elizabeth Jeter, Brianna N Leitzelar, et al.
The Lancet. Oncology
|
December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 18, 2020
<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C Turner, Claire Swift, Lucy Kilburn, et al.
JCO Precision Oncology
|
June 30, 2022
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience
Lorenzo Gerratana, Michael Movarek, Firas Wehbe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2019
Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Oukseub Lee, Megan E Sullivan, Yanfei Xu, et al.
Cancers
|
May 14, 2022
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area
Alain Mina, Carlos Galvez, Reem Karmali, et al.
Breast Cancer Research and Treatment
|
March 2, 2011
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
Virginia G Kaklamani, Kalliopi Siziopikou, Denise Scholtens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 2, 2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
Kathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Breast Cancer Research : BCR
|
April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Kathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Journal of Health Psychology
|
July 28, 2025
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study
Dori M Beeler, Elizabeth Jeter, Brianna N Leitzelar, et al.
The Lancet. Oncology
|
December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Page
of 8